Modern aspects of diagnosis and treatment of chronic cerebral ischemia. Application of naftidrofuryl
https://doi.org/10.21518/2079-701X-2015-18-11-17
Abstract
Chronic cerebral ischemia (CCI) is one of the most common diagnoses in the national neurology, which is now completely absent in most countries and to a certain extent corresponds to vascular cognitive impairment (VCI) in modern foreign literature. The literature data and author's findings on the diagnosis and treatment of CCI are presented. Other diseases may often clinically simulate CCI (anxiety and depressive disorders, primary headaches, peripheral vestibulopathy, Alzheimer's disease) which unfortunately are poorly diagnosed in clinical practice, so patients do not receive effective treatment. Treatment of patients with CCI (VCI) should be focused on managing risk factors for stroke (cessation of smoking and alcohol abuse, sufficient physical activity), normalization of blood pressure (antihypertensive agents), reduction of blood cholesterol levels (statins), antithrombotic therapy (antiplatelet agents and anticoagulants), and administration of drugs that enhance cognitive function. There are findings on the use of naftidrofuryl (Dusopharm) in patients with cognitive impairment.
About the Author
V. A. Parfyonov
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001, 327 с.
2. Дамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно. М.: Медицина, 2005. 1: 231-302.
3. Международная статистическая классификация болезней и проблем, связанных со здоровьем. Десятый пересмотр. (МКБ-10). Женева, 1995.
4. Шмидт Е.В. Классификация сосудистых поражений головного и спинного мозга. Журнал невропатологии и психиатрии. 1985. 9: 1281-1288.
5. Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J, Ames D, Gustafson L et al. Martin Dunitz-2004.
6. Gorelick PB, Scuteri A, Black SE et aL Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011. 42: 2672-2713.
7. Levine DA, Langa KM. Vascular Cognitive Impairment: Disease Mechanisms and The^eu^c Implications. Neurotherapeutics, 2011. 8: 361-373.
8. Яхно Н.Н. Когнитивные расстройства в неврологической практике. Неврологический журнал. 2006. Приложение 1: 4-12.
9. Неверовский Д.В., Случевская С.Ф., Парфенов В.А. Дифференциальный диагноз дисциркуляторной энцефалопатии в амбулаторной практике. Неврология, нейропсихиатрия и психосоматика. 2013. 2: 38-42.
10. Парфенов В.А., Замерград М.В., Мельников О.А. Головокружение: диагностика и лечение, распространенные диагностические ошибки. М.: МИА, 2009. 152 с.
11. Eu^ean Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008. 25: 457-507.
12. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012. 288 с.
13. Kernan WN, Ovbiagele B, Black HR. et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014. 45: 2160-2236.
14. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003. 34: 2475-2481.
15. Baskys A, Hou AC. Vascular dementia: Pharmacological treatment approaches and perspectives. Clinical Interventions in Aging. 2007. 2: 327-335.
16. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012 Dec 12. 12:CD001368.
17. Marcial JM, Perez R, Vargas P, Franqui-Rivera H. Non-Invasive The^y of Peripheral Arterial Disease. Bol Asoc Med P R. 2015. 107: 52-57.
18. Bouvier B, Passeron O, Chup^n M. Psychometric Study of Praxilene. J Med Res. 1974. 2: 59-62.
19. Saldmann F, Funel A, Jacquet P Efficacy of naftidrofuryl in patients with moderate senile dementia. Curr Med Res Opin. 1991. 12: 379389.
20. Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results ofa multicenter, double-blind trial. ClinTher. 2000. 22: 834-844.
21. Moller H, Hartmann A, Kessler C et al. Naftidrofuryl in the treatment of vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 2001. 251: 247-54.
22. Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. The Cochrane Library. 2011, Dec 7(12):CD002955.
23. Белова А.Н., Шакурова Д.Н., Гаязова Е.В. Нафтидрофурил в терапии цереброваскулярных заболеваний: обзор литературы и собственные наблюдения. Неврология, нейропсихиатрия и психосоматика. 2014. 4: 110-115.
24. Squires H, Simpson E, Meng Y, Harnan S, Stevens JW, Wong R et al. A systematic review and economic evaluation of cilosta-zol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011.15: 40-47.
Review
For citations:
Parfyonov VA. Modern aspects of diagnosis and treatment of chronic cerebral ischemia. Application of naftidrofuryl. Meditsinskiy sovet = Medical Council. 2015;(18):11-17. (In Russ.) https://doi.org/10.21518/2079-701X-2015-18-11-17
Views:
1520
Email this article 